palmitoylethanolamide.com.au
HomeResearchCapra 2023

Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies

Capra AP, Ardizzone A, Crupi L, Calapai F, Campolo M, Cuzzocrea S, Esposito E. Biomedicines, 2023; 11(8):2189.

Meta-analysisHumansWith luteolin

This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Meta-analysis
Subjects
5 studies with 441 patients in the review. 3 studies with 327 patients were pooled.
Dose used in the study
700 mg of palmitoylethanolamide with 70 mg of luteolin, once a day
Duration
30 to 90 days
What was measured
Recovery of the sense of smell on the Sniffin' Sticks test

What the authors reported

PEA plus luteolin, given with olfactory training, favoured recovery of smell over conventional therapy. The pooled odds ratio was 3.07 (95% CI 2.22 to 3.92) in a fixed-effects model and 4.28 in a random-effects model, though that confidence interval crossed zero (-0.04 to 8.60). Heterogeneity was high (I² = 89%).

Limits of this study

With heterogeneity this high, the random-effects result is the more cautious reading, and it was borderline. The authors note small samples, short follow-up, a lack of placebo control in some studies, and that all studies were Italian. The review received no external funding.

Source

doi:10.3390/biomedicines11082189

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.